American Journal of Clinical Dermatology

, Volume 13, Issue 6, pp 375–388

Nail Psoriasis

A Review
  • Eugene S. T. Tan
  • Wei-Sheng Chong
  • Hong Liang Tey
Review Article

Abstract

Nail psoriasis is common, occurring in up to half of patients with psoriasis and in 90% of patients with psoriatic arthritis. Left untreated, it may progress to debilitating nail disease, which leads to significant functional impairment.

The most common clinical signs of nail psoriasis are nail plate pitting and onycholysis. Other classical signs include oil drop discoloration, subungual hyperkeratosis, and splinter hemorrhages. The modified Nail Psoriasis Severity Index (mNAPSI) can be used to grade the severity of nail psoriasis, while the Nail Psoriasis Quality of Life Scale (NPQ10) is a questionnaire that evaluates the impact of nail psoriasis on the patient’s functional status and quality of life.

Treatment of nail psoriasis should be individualized according to the patient’s preferences, severity of nail changes, and presence of skin and/or joint involvement. Both topical and intralesional therapies are safe and effective treatment modalities for nail disease, but are limited by poor adherence and pain, respectively. Systemic therapy such as oral retinoids may be considered for widespread nail disease causing significant morbidity. Among biologic agents, tumor necrosis factor-a inhibitors and T-cell-targeted therapies such as ustekinumab may be useful for refractory severe nail psoriasis.

References

  1. 1.
    Gelfand JM, Weinstein R, Porter SB, et al. Prevalence and treatment of psoriasis in the United Kingdom: a population-based study. Arch Dermatol 2005; 141: 1537–41PubMedCrossRefGoogle Scholar
  2. 2.
    Plunkett A, Marks R. A review of the epidemiology of psoriasis vulgaris in the community. Australas J Dermatol 1998; 39: 225–32PubMedCrossRefGoogle Scholar
  3. 3.
    Icen M, Crowson CS, McEvoy MT, et al. Trends in incidence of adult-onset psoriasis over three decades: a population-based study. J Am Acad Dermatol 2009; 60: 394–401PubMedCrossRefGoogle Scholar
  4. 4.
    Gladman DD, Antoni Mease P, et al. Psoriatic arthritis: epidemiology, clinical features, course, and outcome. Ann Rheum Dis 2005; 64 Suppl. 2:14–7Google Scholar
  5. 5.
    Gladman DD, Anhorn KB, Schachter RK, et al. HLA antigens in psoriatic arthritis. J Rheumatol 1986; 13: 586–92PubMedGoogle Scholar
  6. 6.
    Cohen MR, Reda DJ, Clegg DO. Baseline relationships between psoriasis and psoriatic arthritis: analysis of 221 patients with active psoriatic arthritis. Department of Veterans Affairs Cooperative Study Group on Seronegative Spondyloarthropathies. J Rheumatol 1999; 26: 1752–6PubMedGoogle Scholar
  7. 7.
    Samman PD, Fenton DA. The nails in disease. 5th ed. London: Butterworth-Heinemann Ltd., 1994Google Scholar
  8. 8.
    Van Laborde S, Scher RK. Developments in the treatment of nail psoriasis, melanonychia striata, and onychomycosis: a review of the literature. Dermatol Clin 2000; 18: 37–46PubMedGoogle Scholar
  9. 9.
    Augustin M, Reich Blome et al. Nail psoriasis in Germany: epidemiology and burden of disease. Br J Dermatol 2010; 163: 580–5PubMedCrossRefGoogle Scholar
  10. 10.
    Kundakci N, Türsen U, Babiker MO, et al. The evaluation of the socio-demographic and clinical features of Turkish psoriasis patients. Int J Dermatol 2002; 41: 220–4PubMedCrossRefGoogle Scholar
  11. 11.
    Chang CC, Gangaram HB, Hussein SH. Malaysian Psoriasis Registry-preliminary report of a pilot study using a newly revised registry form. Med J Malaysia 2008; 63 Suppl. C: 68–71PubMedGoogle Scholar
  12. 12.
    Myers WA, Gottlieb AB, Mease P. Psoriasis and psoriatic arthritis: clinical features and disease mechanisms. Clin Dermatol 2006; 24: 438–47PubMedCrossRefGoogle Scholar
  13. 13.
    Tham SN, Lim JJ, Tay SH, et al. Clinical observations on nail changes in psoriasis. Ann Acad Med Singapore 1988; 17: 482–5PubMedGoogle Scholar
  14. 14.
    Jiaravuthisan MM, Sasseville D, Vender RB, et al. Psoriasis of the nail: anatomy, pathology, clinical presentation, and a review of the literature on therapy. J Am Acad Dermatol 2007; 57: 1–27PubMedCrossRefGoogle Scholar
  15. 15.
    Rich P, Scher RK. Nail Psoriasis Severity Index: a useful tool for evaluation of nail psoriasis. J Am Acad Dermatol 2003; 49: 206–12PubMedCrossRefGoogle Scholar
  16. 16.
    de Berker D. Management of nail psoriasis. Clin Exp Dermatol 2000; 25: 357–62PubMedCrossRefGoogle Scholar
  17. 17.
    Edwards F, de Berker D. Nail psoriasis: clinical presentation and best practice recommendations. Drugs 2009; 69: 2351–61PubMedCrossRefGoogle Scholar
  18. 18.
    Kovich OI, Soldano AC. Clinical pathologic correlations for diagnosis and treatment of nail disorders. Dermatol Ther 2007; 20: 11–6PubMedCrossRefGoogle Scholar
  19. 19.
    Natarajan V, Nath AK, Thappa DM, et al. Coexistence of onychomycosis in psoriatic nails: a descriptive study. Indian J Dermatol Venereol Leprol 2010; 76: 723PubMedGoogle Scholar
  20. 20.
    Saladi RN, Persaud AN, Rudikoff D, et al. Idiopathic splinter hemorrhages. J Am Acad Dermatol 2004; 50: 289–92PubMedCrossRefGoogle Scholar
  21. 21.
    Francès C, Piette JC, Saada V, et al. Multiple subungual splinter hemorrhages in the antiphospholipid syndrome: a report of five cases and review of the literature. Lupus 1994; 3: 123–8PubMedCrossRefGoogle Scholar
  22. 22.
    Jones SM, Armas JB, Cohen MG, et al. Psoriatic arthritis: outcome of disease subsets and relationship of joint disease to nail and skin disease. Br J Rheumatol 1994; 33: 834–9PubMedCrossRefGoogle Scholar
  23. 23.
    Tan AL, Grainger AJ, Tanner SF, et al. A high-resolution magnetic resonance imaging study of distal interphalangeal joint arthropathy in psoriatic arthritis and osteoarthritis: are they the same? Arthritis Rheum 2006; 54: 1328–33PubMedCrossRefGoogle Scholar
  24. 24.
    Tan AL, Benjamin M, Toumi H, et al. The relationship between the extensor tendon enthesis and the nail in distal in terphalangeal joint disease in psoriatic arthritis: a high-resolution MRI and histological study. Rheumatology (Oxford) 2007; 46: 253–6CrossRefGoogle Scholar
  25. 25.
    McGonagle D. Enthesitis: an autoinflammatory lesion linking nail and joint involvement in psoriatic disease. J Eur Acad Dermatol Venereol 2009; 23 Suppl. 1: 9–13PubMedCrossRefGoogle Scholar
  26. 26.
    Williamson L, Dalbeth N, Dockerty JL, et al. Extended report: nail disease in psoriatic arthritis: clinically important, potentially treatable and often overlooked. Rheumatology (Oxford) 2004; 43: 790–4CrossRefGoogle Scholar
  27. 27.
    Parrish CA, Sobera JO, Elewski BE. Modification of the Nail Psoriasis Severity Index. J Am Acad Dermatol 2005; 53: 745–6PubMedCrossRefGoogle Scholar
  28. 28.
    Cassell SE, Bieber JD, Rich P, et al. The modified Nail Psoriasis Severity Index: validation of an instrument to assess psoriatic nail involvement in patients with psoriatic arthritis. J Rheumatol 2007; 34: 123–9PubMedGoogle Scholar
  29. 29.
    Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI): a simple practical measure for routine clinical use. Clin Exp Dermatol 1994; 19: 210–6PubMedCrossRefGoogle Scholar
  30. 30.
    Ortonne JP, Baran R, Corvest M, et al. Development and validation of nail psoriasis quality of life scale (NPQ10). J Eur Acad Dermatol Venereol 2010; 24: 22–7PubMedCrossRefGoogle Scholar
  31. 31.
    Tosti A, Piraccini BM, Cameli N, et al. Calcipotriol ointment in nail psoriasis: a controlled double-blind comparison with betamethasone dipropionate and salicylic acid. Br J Dermatol 1998; 139: 655–9PubMedCrossRefGoogle Scholar
  32. 32.
    Rigopoulos D, Ioannides D, Prastitis N, et al. Nail psoriasis: a combined treatment using calcipotriol cream and clobetasol propionate cream [letter]. Acta Derm Venereol 2002; 82: 140PubMedCrossRefGoogle Scholar
  33. 33.
    Tzung TY, Chen CY, Yang CY, et al. Calcipotriol used as monotherapy or combination therapy with betamethasone dipropionate in the treatment of nail psoriasis. Acta Derm Venereol 2008; 88: 279–80PubMedGoogle Scholar
  34. 34.
    Wolf R, Tur E, Brenner S. Corticosteroid-induced ‘disappearing digit’. J Am Acad Dermatol 1990; 23: 755–6PubMedCrossRefGoogle Scholar
  35. 35.
    Deffer TA, Goette DK. Distal phalangeal atrophy secondary to topical steroid therapy. Arch Dermatol 1987; 123: 571–2PubMedCrossRefGoogle Scholar
  36. 36.
    Scott LJ, Dunn CJ, Goa KL. Calcipotriol ointment: a review of its use in the management of psoriasis. Am J Clin Dermatol 2001; 2: 95–120PubMedCrossRefGoogle Scholar
  37. 37.
    Fredriksson T. Topically applied fluorouracil in the treatment of psoriatic nails. Arch Dermatol 1974; 110: 735–6PubMedCrossRefGoogle Scholar
  38. 38.
    de Jong EM, Menke HE, van Praag MC, et al. Dystrophic psoriatic fingernails treated with 1% 5-fluorouracil in a nail penetration-enhancing vehicle: a double-blind study. Dermatology 1999; 199: 313–8PubMedCrossRefGoogle Scholar
  39. 39.
    Kemény L, Ruzicka T, Braun-Falco O. Dithranol: a review of the mechanism of action in the treatment of psoriasis vulgaris. Skin Pharmacol 1990; 3: 1–20PubMedCrossRefGoogle Scholar
  40. 40.
    Yamamoto T, Katayama I, Nishioka K. Topical anthralin therapy for refractory nail psoriasis. J Dermatol 1998; 25: 231–3PubMedGoogle Scholar
  41. 41.
    Duvic M, Nagpal S, Asano AT, et al. Molecular mechanisms of tazarotene action in psoriasis. J Am Acad Dermatol 1997; 37: S18–24PubMedCrossRefGoogle Scholar
  42. 42.
    Scher RK, Stiller M, Zhu YI. Tazarotene 0.1% gel in the treatment of fingernail psoriasis: a double-blind, randomized, vehicle-controlled study. Cutis 2001; 68: 355–8PubMedGoogle Scholar
  43. 43.
    Bianchi L, Soda R, Diluvio L, et al. Tazarotene 0.1% gel for psoriasis of the fingernails and toenails: an open, prospective study. Br J Dermatol 2003; 149: 207–9PubMedCrossRefGoogle Scholar
  44. 44.
    Rigopoulos D, Gregoriou S, Katsambas A. Treatment of psoriatic nails with tazarotene cream 0.1 % vs. clobetasol propionate 0.05% cream: a double-blind study. Acta Derm Venereol 2007; 87: 167–8PubMedCrossRefGoogle Scholar
  45. 45.
    Weindl G, Roeder A, Schäfer-Korting M, et al. Receptor-selective retinoids for psoriasis: focus on tazarotene. Am J Clin Dermatol 2006; 7: 85–97PubMedCrossRefGoogle Scholar
  46. 46.
    Cannavò SP, Guarneri F, Vaccaro M, et al. Treatment of psoriatic nails with topical cyclosporin: a prospective, randomized placebo-controlled study. Dermatology 2003; 206: 153–6PubMedCrossRefGoogle Scholar
  47. 47.
    Tosti A, Guerra L, Bardazzi F, et al. Topical ciclosporin in nail psoriasis [letter]. Dermatologica 1990; 180: 110PubMedCrossRefGoogle Scholar
  48. 48.
    Hermann RC, Taylor RS, Ellis CN, et al. Topical ciclosporin for psoriasis: in vitro skin penetration and clinical study. Skin Pharmacol 1988; 1: 246–9PubMedCrossRefGoogle Scholar
  49. 49.
    Prins AM, Vos Franssen EJ. Instability of topical ciclosporin emulsion for nail psoriasis. Dermatology 2007; 215: 362–3PubMedCrossRefGoogle Scholar
  50. 50.
    Lin AN. Innovative use of topical calcineurin inhibitors. Dermatol Clin 2010; 28: 535–45PubMedCrossRefGoogle Scholar
  51. 51.
    de Berker D. Management of psoriatic nail disease. Semin Cutan Med Surg 2009; 28: 39–43PubMedCrossRefGoogle Scholar
  52. 52.
    Grover C, Bansal S, Nanda S, et al. Efficacy of triamcinolone acetonide in various acquired nail dystrophies. J Dermatol 2005; 32: 963–8PubMedGoogle Scholar
  53. 53.
    Saleem K, Azim W. Treatment of nail psoriasis with a modified regimen of steroid injections. J Coll Physicians Surg Pak 2008; 18: 78–81PubMedGoogle Scholar
  54. 54.
    de Berker DA, Lawrence CM. A simplified protocol of steroid injection for psoriatic nail dystrophy. Br J Dermatol 1998; 138: 90–5PubMedCrossRefGoogle Scholar
  55. 55.
    Marx JL, Scher RK. Response of psoriatic nails to oral photochemotherapy. Arch Dermatol 1980; 116: 1023–4PubMedCrossRefGoogle Scholar
  56. 56.
    Handfield-Jones SE, Boyle J, Harman RR. Local PUVA treatment for nail psoriasis. Br J Dermatol 1987; 116: 280–1PubMedCrossRefGoogle Scholar
  57. 57.
    Stern DK, Creasey AA, Quijije J, et al. UV-A and UV-B penetration of normal human cadaveric fingernail plate. Arch Dermatol 2011; 147: 439–41PubMedCrossRefGoogle Scholar
  58. 58.
    Hern S, Stanton AW, Mellor RH, et al. In vivo quantification of the structural abnormalities in psoriatic microvessels before and after pulsed dye laser treatment. Br J Dermatol 2005; 152: 505–11PubMedCrossRefGoogle Scholar
  59. 59.
    Oram Y, Karincaoğlu Y, Koyuncu E, et al. Pulsed dye laser in the treatment of nail psoriasis. Dermatol Surg 2010; 36: 377–81PubMedCrossRefGoogle Scholar
  60. 60.
    Fernández-Guarino M, Harto A, Sánchez-Ronco M, et al. Pulsed dye laser vs. photodynamic therapy in the treatment of refractory nail psoriasis: a comparative pilot study. J Eur Acad Dermatol Venereol 2009; 23: 891–5PubMedCrossRefGoogle Scholar
  61. 61.
    Finnerty EF. Successful treatment of psoriasis of the nails. Cutis 1979; 23: 43–4PubMedGoogle Scholar
  62. 62.
    Yu RC, King CM. A double-blind study of superficial radiotherapy in psoriatic nail dystrophy. Acta Derm Venereol 1992; 72: 134–6PubMedGoogle Scholar
  63. 63.
    Kwang TY, Nee TS, Seng KT. A therapeutic study of nail psoriasis using electron beams [letter]. Acta Derm Venereol 1995; 75: 90PubMedGoogle Scholar
  64. 64.
    Lindelöf B. Psoriasis of the nails treated with grenz rays: a double-blind bilateral trial. Acta Derm Venereol 1989; 69: 80–2PubMedGoogle Scholar
  65. 65.
    Brazzelli V, Martinoli S, Prestinari F, et al. An impressive therapeutic result of nail psoriasis to acitretin. J Eur Acad Dermatol Venereol 2004; 18: 229–30PubMedCrossRefGoogle Scholar
  66. 66.
    López V, Molina I, Martí N, et al. Severe nail psoriasis with a rapid response to acitretin. Clin Exp Dermatol 2009; 34: e332–3PubMedCrossRefGoogle Scholar
  67. 67.
    Tosti A, Ricotti C, Romanelli P, et al. Evaluation of the efficacy of acitretin therapy for nail psoriasis. Arch Dermatol 2009; 145: 269–71PubMedCrossRefGoogle Scholar
  68. 68.
    Piraccini BM, Tosti A, Iorizzo M, et al. Pustular psoriasis of the nails: treatment and long-term follow-up of 46 patients. BrJ Dermatol 2001; 144:1000–5CrossRefGoogle Scholar
  69. 69.
    Sbidian E, Maza A, Montaudié H, et al. Efficacy and safety of oral retinoids in different psoriasis subtypes: a systematic literature review. J Eur Acad Dermatol Venereol 2011; 25: 28–33PubMedCrossRefGoogle Scholar
  70. 70.
    Baran R. Etretinate and the nails (study of 130 cases) possible mechanisms of some side-effects. Clin Exp Dermatol 1986; 11: 148–52PubMedCrossRefGoogle Scholar
  71. 71.
    Syuto T, Abe M, Ishibuchi H, et al. Successful treatment of psoriatic nails with low-dose cyclosporine administration. Eur J Dermatol 2007; 17: 248–9PubMedGoogle Scholar
  72. 72.
    Mahrle G, Schulze HJ, Färber L, et al. Low-dose short-term cyclosporine versus etretinate in psoriasis: improvement of skin, nail, and joint involvement. J Am Acad Dermatol 1995; 32: 78–88PubMedCrossRefGoogle Scholar
  73. 73.
    Feliciani C, Zampetti A, Forleo P, et al. Nail psoriasis: combined therapy with systemic cyclosporin and topical calcipotriol. J Cutan Med Surg 2004; 8: 122–5PubMedCrossRefGoogle Scholar
  74. 74.
    Gümüşel M, Ozdemir M, Mevlitogğlu I, et al. Evaluation of the efficacy of methotrexate and cyclosporine therapies on psoriatic nails: a one-blind, randomized study. J Eur Acad Dermatol Venereol 2011 Sep; 25(9): 1080–4PubMedCrossRefGoogle Scholar
  75. 75.
    Carson KR, Focosi D, Major EO, et al. Monoclonal antibody-associated progressive multifocal leucoencephalopathy in patients treated with ritux-imab, natalizumab, and efalizumab: a Review from the Research on Adverse Drug Events and Reports (RADAR) Project. Lancet Oncol 2009; 10: 816–24PubMedCrossRefGoogle Scholar
  76. 76.
    Kothary N, Diak IL, Brinker A, et al. Progressive multifocal leukoencephalopathy associated with efalizumab use in psoriasis patients. J Am Acad Dermatol 2011; 65: 546–51PubMedCrossRefGoogle Scholar
  77. 77.
    Hussain W, Coulson I, Owen C. Severe recalcitrant nail psoriasis responding dramatically to infliximab: report of two patients. Clin Exp Dermatol 2008; 33: 520–2PubMedCrossRefGoogle Scholar
  78. 78.
    Reich K, Nestle FO, Papp K, et al. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. Lancet 2005; 366: 1367–74PubMedCrossRefGoogle Scholar
  79. 79.
    Reich K, Ortonne JP, Kerkmann U, et al. Skin and nail responses after 1 year of infliximab therapy in patients with moderate-to-severe psoriasis: a retrospective analysis of the EXPRESS Trial. Dermatology 2010; 221: 172–8PubMedCrossRefGoogle Scholar
  80. 80.
    Rich P, Griffiths CE, Reich K, et al. Baseline nail disease in patients with moderate to severe psoriasis and response to treatment with infliximab during 1 year. J Am Acad Dermatol 2008; 58: 224–31PubMedCrossRefGoogle Scholar
  81. 81.
    Fabroni C, Gori A, Troiano M, et al. Infliximab efficacy in nail psoriasis. a retrospective study in 48 patients. J Eur Acad Dermatol Venereol 2011; 25: 549–53PubMedCrossRefGoogle Scholar
  82. 82.
    Rigopoulos D, Gregoriou S, Stratigos A, et al. Evaluation of the efficacy and safety of infliximab on psoriatic nails: an unblinded, nonrandomized, open-label study. Br J Dermatol 2008; 159: 453–6PubMedCrossRefGoogle Scholar
  83. 83.
    Saurat JH, Stingl G, Dubertret L, et al. Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION). Br J Dermatol 2008; 158: 558–66PubMedCrossRefGoogle Scholar
  84. 84.
    Rigopoulos D, Gregoriou S, Lazaridou E, et al. Treatment of nail psoriasis with adalimumab: an open label unblinded study. J Eur Acad Dermatol Venereol 2010; 24: 530–4PubMedCrossRefGoogle Scholar
  85. 85.
    Van den Bosch F, Manger B, Goupille P, et al. Effectiveness of adalimumab in treating patients with active psoriatic arthritis and predictors of good clinical responses for arthritis, skin and nail lesions. Ann Rheum Dis 2010; 69: 394–9PubMedCrossRefGoogle Scholar
  86. 86.
    Galindo MP, Bartlett BL, Gewirtzman A, et al. Etanercept: an overview of its role in the treatment of psoriasis. Expert Opin Drug Metab Toxicol 2008; 4: 305–10PubMedCrossRefGoogle Scholar
  87. 87.
    Bissonnette R. Etanercept for the treatment of psoriasis. Skin Therapy Lett 2006; 11: 1–4PubMedGoogle Scholar
  88. 88.
    Coelho JD, Diamantino F, Lestre S, et al. Treatment of severe nail psoriasis with etanercept. Indian J Dermatol Venereol Leprol 2011; 77: 72–4PubMedCrossRefGoogle Scholar
  89. 89.
    Rallis E, Stavropoulou E, Rigopoulos D, et al. Rapid response of nail psoriasis to etanercept. J Rheumatol 2008; 35: 544–5PubMedGoogle Scholar
  90. 90.
    Luger TA, Barker J, Lambert J, et al. Sustained improvement in joint pain and nail symptoms with etanercept therapy in patients with moderate-to-severe psoriasis. J Eur Acad Dermatol Venereol 2009; 23: 896–904PubMedCrossRefGoogle Scholar
  91. 91.
    Barrera MV, Habicheyn S, Mendiola MV, et al. Etanercept in the treatment and retreatment of psoriasis in daily clinical practice. Eur J Dermatol 2008; 18: 683–7PubMedGoogle Scholar
  92. 92.
    Lawry M. Biological therapy and nail psoriasis. Dermatol Ther 2007; 20: 60–7PubMedCrossRefGoogle Scholar
  93. 93.
    Krueger GG, Callis KP. Development and use of alefacept to treat psoriasis. J Am Acad Dermatol 2003; 49 (2 Suppl.): S87–97PubMedCrossRefGoogle Scholar
  94. 94.
    Parrish CA, Sobera JO, Robbins CM, et al. Alefacept in the treatment of psoriatic nail disease: a proof of concept study. J Drugs Dermatol 2006; 5: 339–40PubMedGoogle Scholar
  95. 95.
    Körver JE, Langewouters AM, Van De Kerkhof PC, et al. Therapeutic effects of a 12-week course of alefacept on nail psoriasis. J Eur Acad Dermatol Venereol 2006; 20: 1252–5PubMedCrossRefGoogle Scholar
  96. 96.
    Cassetty CT, Alexis AF, Shupack JL, et al. Alefacept in the treatment of psoriatic nail disease: a small case series. J Am Acad Dermatol 2005; 52: 1101–2PubMedCrossRefGoogle Scholar
  97. 97.
    Laws PM, Warren RB. Ustekinumab for the treatment of psoriasis. Expert Rev Clin Immunol 2011; 7: 155–64PubMedCrossRefGoogle Scholar
  98. 98.
    Krulig E, Gordon KB. Ustekinumab: an evidence-based review of its effectiveness in the treatment of psoriasis. Core Evid 2010; 5: 11–22PubMedGoogle Scholar
  99. 99.
    Patsatsi A, Kyriakou A, Sotiriadis D. Ustekinumab in nail psoriasis: an open-label, uncontrolled, nonrandomized study. J Dermatolog Treat. Epub 2011 Aug8Google Scholar

Copyright information

© Springer International Publishing AG 2012

Authors and Affiliations

  • Eugene S. T. Tan
    • 1
  • Wei-Sheng Chong
    • 1
  • Hong Liang Tey
    • 1
  1. 1.National Skin CentreSingapore

Personalised recommendations